The oligometastatic and oligoprogressive disease states have been recently recognized as
common clinical scenarios in the management of non-small cell lung cancer (NSCLC). As a …

More than half of all patients with non–small cell lung cancer (NSCLC) have metastatic
disease at the time of diagnosis. A subset of these patients has oligometastatic disease …

Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are
becoming an integral component in the treatment of oligometastatic disease in non–small …

Patients with non‐small cell lung cancer (NSCLC) at stage IV have typically been
considered incurable. Nonetheless, there is growing evidence that certain patient groups …

Oligometastatic non-small cell lung cancer (NSCLC) has been recognized as a unique, yet
common, clinical entity over the past 2-3 decades. Numerous retrospective series and early …

Oligometastatic non-small cell lung cancer encompasses a number of distinct clinical
scenarios with a pattern of limited tumour burden on imaging. Delivering local ablative …

Patients with nonsmall cell lung cancer and limited metastatic disease have been defined as
oligometastatic if local ablative therapy of all lesions is amenable. Evidence from different …

Oligometastatic Non‐Small Cell Lung Cancer (NSCLC) presents a unique opportunity for
potential curative therapy. Improved cancer staging using PET/CT, MRI, and future cellular …

Patients with oligometastatic (OM) non-small cell lung cancer (NSCLC) have favorable
outcomes compared to patients presenting with diffuse metastatic disease. Recent …

Simple Summary Approximately 7–50% of patients with non-small-cell lung cancer (NSCLC)
develop oligometastases, which are new tumors found in another part of the body, arising …